Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

This study is testing whether GLP-1 receptor agonists — the class of drugs that includes medications like semaglutide (Ozempic/Wegovy) — can improve blood sugar control and support weight loss in people who have a spinal cord injury and Type 2 diabetes. **You may be eligible if...** - You are between 18 and 70 years old - You had a spinal cord injury more than one year ago (injury level between C2 and L2) - You have Type 2 diabetes managed with diet and metformin only (no major dose changes in the last 3 months) - Your HbA1c (average blood sugar) is between 6.0% and 9.0% - Your BMI is over 22 **You may NOT be eligible if...** - You are on insulin or other diabetes medications besides metformin - You have Type 1 diabetes - You are pregnant or planning to become pregnant - You have conditions that make this class of medication unsafe Talk to your doctor to see if this trial is right for you.